- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02987140
Understand FoG in PD: Behavioral Physiology and Clinical Application
Understand Freezing of Gait in Parkinson's Disease: Behavioral Physiology and Clinical Application
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Freezing of gait (FoG) is a debilitating symptom for patients with Parkinson's disease (PD). FoG not only impairs walking but also significantly increase fall risks and decrease quality of life for patients with PD. Despite the critical consequences, the mechanisms associated with this phenomenon are not well understood.
Clinically, FoG often occurs when individuals with PD are approaching a narrow pathway or crossing a busy street. This observation leads to the hypothesis that FoG is associated with context-dependent motor performance, a phenomenon that an individual demonstrate poorer performance if the learned motor task is carried out in an unfamiliar context. Whether the occurrence of freezing episodes is a result of context-dependency has not been systematically investigated. Moreover, the changes in corticomotor excitability associated with FoG have not been well-established.
Objectives: The objectives of this proposal are to understand the behavioral and neurophysiological mechanisms of FoG. The specific aim is to examine the behavioral changes in context-dependency and changes in corticomotor excitability associated with FoG.
Methods: a total of 70 participants, including PD patients with FoG, PD patients without FoG, and age-matched non-disabled adults, will be recruited. The participants will undergo behavioral and neurophysiological examinations. Behavioral evaluations will include context-dependent motor performance, FoG, disease severity, and walking and balance functions. Transcranial magnetic stimulation and electroencephalogram will be used to measure corticomotor excitability of the participants. Analysis of variance (ANOVA) and regression analysis will be performed to compare and determine the relationship between FoG, behavioral outcomes, and corticomotor excitability. Statistical significance level is set at p < 0.05.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Ya-Yun Lee, PHD
- Phone Number: 02-33668155
- Email: yayunlee@ntu.edu.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Individuals with Parkinson's disease
- Healthy control subjects
Exclusion criteria:
- unable to follow the instructions
- have other neurological diseases other than PD
- have pacemaker implanted in their body
- have a history of seizure
- have a family history of epilepsy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SCREENING
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: PD+FoG
PD patients with FoG
|
Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment.
On the second day, the participants will receive the TMS assessment.
|
|
ACTIVE_COMPARATOR: PD-FoG
PD patients without FoG
|
Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment.
On the second day, the participants will receive the TMS assessment.
|
|
ACTIVE_COMPARATOR: Control
age-matched non-disabled adults
|
Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment.
On the second day, the participants will receive the TMS assessment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
New Freezing of Gait Questionnaire (NFOG-Q)
Time Frame: 30 mins
|
The New Freezing of Gait Questionnaire (NFOG-Q) will be used to evaluate the freezing frequency and severity of the patients with PD.
It composes of 3 parts; in the first part, a video clip will be shown to the participants with PD and help to classify whether an individual is a freezer or non-freezer.
The second and third part of the questionnaire is designed for freezers only.
PartⅡassesses the severity of FoG according to the frequency and duration of the freezing episodes, while PartⅢevaluates the impact of freezing on daily activities, such as walking.
The reliability and internal consistency of the NFOG-Q have been well-established for patients with PD (Nieuwboer et al., 2009).
|
30 mins
|
|
Context-dependent behavior
Time Frame: 40 mins
|
A modified finger sequence task is specifically designed to evaluate context-dependent behavior for patients with PD. The participants will be instructed to put their index and middle fingers of both hands on a designated location of an enlarged key-board. The participants will first practice the three sequences for a total of 324 practice trials on the first day. Ten minutes and 24 hours after practice, to control for the medication status, the participants will be tested under the SAME and SWITCH conditions.With these 2 testing conditions, we will be able to calculate a variable called Switch Cost, which is the performance difference between the SWTICH and the SAME conditions normalized by the SAME condition [100% * (SWITCH - SAME)/SAME]. The Switch Cost will be used as an indicator of context-dependency. |
40 mins
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Unified Parkinson's Disease Rating Scale (UPDRS)
Time Frame: 30 mins
|
The UPDRS contains 4 sections, and PartIIIwill be used in this study to evaluate the motor disturbances of patients with PD.
Excellent internal consistency and validity has been established for UPDRS (Goetz et al., 2008).
|
30 mins
|
|
Montreal Cognitive Assessment (MoCA)
Time Frame: 10 mins
|
The MoCA evaluates several cognitive domains, including visuospatial processing, naming, short-term memory, digit forward and backward span, verbal fluency, abstract concept, counting, and orientation.
The MoCA has been found to be a valid and reliable tool to screen for cognitive dysfunctions in patients with PD (Gill, Freshman, Blender, & Ravina, 2008).
|
10 mins
|
|
The Stroop Color-Word test
Time Frame: 5 mins
|
The Stroop Color-Word test involves congruent and incongruent conditions.The goal of the participants is to read out the ink color of the word, but not the color word name itself, as accurately and as soon as possible (Dubois et al., 2007; Ridley, Johnson, & Braisted, 1978).
|
5 mins
|
|
10-Meter Walk Test (10MWT)
Time Frame: 5 mins
|
10MWT assesses the walking ability of the participants.
The participants will be instructed to walk in their comfortable walking speed and their fastest walking speed for 10 meters.
Gait speed, stride length, and cadence will be calculated.
|
5 mins
|
|
The Timed Up and Go (TUG) test
Time Frame: 5 mins
|
The TUG evaluates the balance ability of the participants.
The participants will be seated on a comfortable chair with hip and knee flexed at 90 Upon a 'Go' signal, the participants will stand up from the chair, walk 3 meters, turn around, and sit back down to the chair.
The time to complete the procedure will be measured.
|
5 mins
|
|
The Parkinson's Disease Questionnaire(PDQ-39)
Time Frame: 10 mins
|
The PDQ-39 specifically assess quality of life in patients with PD.
PDQ-39 contains 39 questions embedded in 8 different domains.
PDQ-39 has now become the most widely accepted and reliable measure to determine the overall health status for patients with PD (Jenkinson, Peto, Fitzpatrick, Greenhall, & Hyman, 1995).
|
10 mins
|
|
Transcranial magnetic stimulation
Time Frame: 45 mins
|
To compare the neurophysiological characteristics of PD patients with FoG, PD patients without FoG, and non-disabled adults, a TMS device (The Magstim Company Ltd, Whitland, UK) will be used.
TMS outcomes will include resting motor threshold (RMT), motor evoked potentials (MEPs), cortical silent period (CSP), short-interval intracortical inhibition (SICI), long-interval intracortical inhibition (LICI), and intracortical facilitation (ICF).
|
45 mins
|
|
Electroencephalogram (EEG)
Time Frame: 40 mins
|
While performing the modified finger sequence task, the electroencephalogram (EEG) will be used to monitor and record brain activity.
Comparisons will be made between the first block of practice, last block of practice, and the two testing conditions.
|
40 mins
|
|
The short FoG and festination assessment score
Time Frame: 20 mins
|
The short FoG and festination assessment score, developed by Ziegler and colleagues (2010), will be used to clinically assess freezing and festination episodes over a short time course.
The participants will initially sit on a chair for 30 seconds, then they will be instructed to stand up and walk to a floor mark with 40 radius and make 360 turn clockwise and counter-clockwise.
Then, the participants will walk through a door, turn around and walk back to the chair.
The participants will be required to walk in a fast but safe speed.
This evaluation approach has been demonstrated to be feasible and reliable for assessing the severity of freezing and festination.
|
20 mins
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201606057RINA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
Bezmialem Vakif UniversityIstanbul University - CerrahpasaNot yet recruitingParkinson Disease | PARKINSON DISEASE (Disorder) | Parkinson Disease (PD), Postural Balance
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
Clinical Trials on Clinical evaluations
-
Pierre Fabre Dermo CosmetiqueCompletedAtopic DermatitisFrance
-
University Hospital, BrestTerminated
-
European Organisation for Research and Treatment...UnknownDrug Induced Interstitial Lung Disease (DIILD) Cancer Patients
-
Azienda Ospedaliero-Universitaria di ModenaCompleted
-
Ottawa Heart Institute Research CorporationNot yet recruitingMenopause | Sleep Disruption | T2DM
-
IRCCS Eugenio MedeaCompletedDevelopmental Psychological DisorderItaly
-
KU LeuvenUniversitaire Ziekenhuizen KU Leuven; Nij Smellinghe Hospital DrachtenNot yet recruitingLower Limb LymphedemaBelgium, Netherlands
-
IRCCS San RaffaeleFederico II University; Istituto Auxologico Italiano; University of CatanzaroNot yet recruitingBone Health | Pituitary Dysfunction | Obesity; Endocrine
-
University Hospital, MontpellierBeziers HospitalRecruiting
-
Fondation Korian pour le Bien VieillirGerontopôle des Pays de la LoireCompleted